Peripheral Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented By Treatment Type (Anti-depressant, Anti-convulsants, Pain relievers, Others), By Application and Geography.

Market Snapshot

Peripheral Neuritis Treatment Market Report
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.3 %
Peripheral Neuritis Treatment Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Peripheral Neuritis Treatment Market is expected to register a CAGR of 3.3% during the forecast period. With the growing burden of diseases associated with peripheral neuritis and increasing number of geriatric populations, it is expected to impact positively on the peripheral neuritis treatment market growth. Peripheral neuropathy is a side-effect to chemotherapy in cancer patients. According to the study published in American Neurological Association, in 2017, around 30%-40% patients that receive neurotoxic chemotherapy suffers from peripheral neuropathy condition. Thus, treatment for such conditions becomes mandatory. 

Scope of the Report

Peripheral neuritis, also known as peripheral neuropathy refers to the damaging of peripheral nervous system which leads to the failure of sending signals to/from the brain, to/from the spinal cord and other body parts. Some of its causes include physical trauma, diabetes, autoimmune diseases, etc. Peripheral Neuritis Treatment Market is segmented By Treatment Type, Application and Geography.

By Treatment Type
Pain Relievers
By Application
Autoimmune Disease
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Diabetes Segment is Expected to Hold a Major Share in the Peripheral Neuritis Treatment Market

  • Diabetes is a disease that usually occurs when pancreas fail to produce enough amount of insulin or the body fails to use it effectively. Severity of the diabetes can lead to damage in the blood vessels, nerve damage (neuropathy), etc. According to International Diabetes Federation, in 2019, around 463 million people were diagnosed with diabetes.
  • Diabetes neuropathy refers to loss of sensation in limbs, mostly legs and feet. It is considered as the most commonly occurring complication in diabetic people. Over the time it can lead to foot ulcers and lower limb amputation. For instance, around 50% of people diabetes are likely to be affected by neuropathy, according to the American Diabetes Association.
Diabetic Neuropathy Treatment Market Share

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global peripheral neuritis treatment market due to increasing aging population and higher prevalence rate of diabetic people. Peripheral neuritis is very commonly found in geriatric population, majorly in case of diabetes. According to the Census Bureau of U.S., approximately 56,052 population living in U.S., in 2020, is 65 years and above. Furthermore, according to the National Safety Council, around 4.5 million people were injured in road accidents. Physical trauma is likely to cause single-nerve injury. Injuries through road accidents, medical procedures, etc. can damage the nerve leading to peripheral neuritis. Thus, these factors are expected to impact positively on peripheral neuritis treatment market growth in North America.

Diabetic Neuropathy Treatment Market Analysis

Competitive Landscape

The Peripheral Neuritis Treatment Market is fragmented and consists of several major players. Companies are constantly indulged in developing new treatments related to peripheral neuropathy. For instance, Biogen, is developing a new treatment type for neuropathic pain. It is a biologics - BIIB095, currently in it's first phase of clinical trial. It acts as a blocker for NaV channel which is the target pain in case of neuropathy. Some of the key players are Eli Lilly & Co., GlaxoSmithKline LLC, Takeda Pharmaceutical & Co. Ltd. (Shire Development LLC), Novartis Pharmaceutical Corporation, Mallinckrodt Pharmaceuticals (Specgx LLC), Cipher Pharmaceuticals Inc., Johnson & Johnson (Janssen Pharmaceutical Inc.) , Pfizer Inc., Amneal Pharmaceuticals LLC, Apotex Inc and Mylan Pharmaceuticals Inc.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Diseases

      2. 4.2.2 Increasing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment Type

      1. 5.1.1 Anti-depressants

      2. 5.1.2 Anti-convulsants

      3. 5.1.3 Pain Relievers

      4. 5.1.4 Others

    2. 5.2 By Application

      1. 5.2.1 Diabetes

      2. 5.2.2 Thyroid

      3. 5.2.3 Autoimmune Disease

      4. 5.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Amneal Pharmaceuticals LLC

      2. 6.1.2 Apotex Inc.

      3. 6.1.3 Cipher Pharmaceuticals Inc.

      4. 6.1.4 Eli Lilly & Co.

      5. 6.1.5 GlaxoSmithKline LLC

      6. 6.1.6 Johnson & Johnson (Janssen Pharmaceutical Inc.)

      7. 6.1.7 Mylan Pharmaceuticals Inc.

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Takeda Pharmaceuticals & Co. Ltd. (Shire Development LLC)

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Peripheral Neuritis Treatment Market market is studied from 2018 - 2026.

The Peripheral Neuritis Treatment Market is growing at a CAGR of 3.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lilly & Co. , GlaxoSmithKline LLC , Pfizer Inc. , Novartis Pharmaceutical Corporation , Mylan Pharmaceuticals Inc. are the major companies operating in Peripheral Neuritis Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!